Dobutamine Panpharma

What Is Dobutamine Panpharma and What Is It Used For?

Quick Answer: Dobutamine Panpharma is an intravenous inotropic drug containing dobutamine hydrochloride 12.5 mg/ml. It is used to provide short-term hemodynamic support in patients with acute heart failure, cardiogenic shock, and during cardiac stress testing.

Dobutamine belongs to the class of sympathomimetic amines and acts primarily as a beta-1 adrenergic receptor agonist. Its principal therapeutic effect is to increase the force of contraction of the heart muscle (positive inotropy), thereby improving cardiac output in patients whose hearts are not pumping effectively. Unlike many other catecholamines, dobutamine achieves this increase in cardiac output with a relatively modest effect on heart rate, making it particularly valuable in the management of acute heart failure.

The medication was first developed in the 1970s by Eli Lilly and Company as a synthetic catecholamine designed to provide selective inotropic support. Since then, it has become one of the most widely used inotropic agents in critical care medicine worldwide. Dobutamine is listed on the World Health Organization’s Model List of Essential Medicines, underscoring its importance in modern healthcare.

Dobutamine Panpharma is manufactured by Panpharma and supplied as a concentrated solution (12.5 mg/ml) that must be diluted before intravenous administration. It is exclusively used in hospital settings, primarily in intensive care units (ICUs), cardiac care units (CCUs), and operating theatres where continuous hemodynamic monitoring is available.

Approved Indications

Dobutamine is indicated for the following clinical situations:

• Acute decompensated heart failure: Including both systolic and combined systolic-diastolic heart failure with low cardiac output, where inotropic support is required to maintain adequate tissue perfusion.
• Cardiogenic shock: As part of the hemodynamic management of cardiogenic shock, often used in combination with vasopressors and mechanical circulatory support devices.
• Cardiac surgery: Perioperative inotropic support during and after cardiac surgery, including coronary artery bypass grafting (CABG) and valve replacement procedures.
• Cardiac stress testing: As a pharmacological stressor in dobutamine stress echocardiography (DSE) for patients who cannot perform adequate physical exercise to evaluate coronary artery disease.
• Septic shock with myocardial dysfunction: When echocardiographic evidence demonstrates impaired cardiac contractility in the setting of sepsis, as recommended by the Surviving Sepsis Campaign guidelines.

Mechanism of Action

Dobutamine exerts its pharmacological effects through stimulation of adrenergic receptors. It is a racemic mixture of two enantiomers, each with distinct receptor activity. The (-)-enantiomer is primarily an alpha-1 agonist, while the (+)-enantiomer is a potent beta-1 and beta-2 agonist and alpha-1 antagonist. The net clinical effect is predominantly beta-1 mediated inotropy.

At the cellular level, dobutamine’s stimulation of beta-1 receptors activates adenylyl cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP) levels. This leads to activation of protein kinase A, which phosphorylates calcium channels and increases calcium influx into cardiomyocytes, thereby enhancing contractile force. The drug’s effect begins within 1–2 minutes of starting the infusion, with peak effects typically achieved within 10 minutes.

An important clinical advantage of dobutamine is that it increases cardiac output without significantly increasing myocardial oxygen demand relative to the increase in cardiac work. This is partly because dobutamine reduces left ventricular filling pressures (preload) through improved cardiac efficiency, which can indirectly reduce pulmonary congestion.

What Should You Know Before Taking Dobutamine Panpharma?

Quick Answer: Dobutamine should not be used in patients with hypertrophic obstructive cardiomyopathy (HOCM) or pheochromocytoma. Caution is required in patients with atrial fibrillation, severe hypertension, recent myocardial infarction, or hypokalaemia. Close monitoring of heart rhythm, blood pressure, and fluid balance is essential.

Contraindications

Dobutamine must not be administered in the following circumstances:

• Hypertrophic obstructive cardiomyopathy (HOCM): Dobutamine increases the dynamic outflow tract obstruction in HOCM, potentially causing dangerous hypotension and arrhythmias. This is an absolute contraindication.
• Pheochromocytoma: The combination of endogenous catecholamine excess and exogenous dobutamine can precipitate a hypertensive crisis.
• Known hypersensitivity: Patients with documented allergy to dobutamine or any excipient in the formulation, including sodium metabisulfite (which may cause allergic reactions in sulfite-sensitive individuals, particularly those with asthma).
• Uncorrected mechanical obstruction: Conditions such as severe aortic stenosis, cardiac tamponade, or constrictive pericarditis where increased contractility cannot improve cardiac output due to mechanical outflow limitation.

Warnings and Precautions

Special caution is required in the following situations:

• Atrial fibrillation: Dobutamine facilitates atrioventricular (AV) conduction and may increase ventricular rate in patients with uncontrolled atrial fibrillation. Digitalization or rate control should be established before commencing dobutamine.
• Acute myocardial infarction: While dobutamine may be necessary for cardiogenic shock post-MI, it can increase myocardial oxygen demand and potentially extend the infarct area. Use with extreme caution and at the lowest effective dose.
• Hypovolaemia: Volume depletion must be corrected before or during dobutamine administration, as the drug’s vasodilatory properties may exacerbate hypotension in hypovolaemic patients.
• Severe ventricular arrhythmias: Dobutamine can provoke or worsen ventricular tachycardia and ventricular fibrillation, particularly in patients with pre-existing arrhythmias or electrolyte abnormalities.
• Hypokalaemia: Potassium levels should be corrected before starting dobutamine, as hypokalaemia increases the risk of cardiac arrhythmias. Regular electrolyte monitoring is essential.
• Diabetes mellitus: Dobutamine may transiently increase blood glucose levels through stimulation of hepatic glycogenolysis. Blood glucose monitoring is recommended in diabetic patients.

Pregnancy and Breastfeeding

There are limited data on the use of dobutamine during pregnancy. Animal studies have not demonstrated teratogenic effects, but dobutamine should only be used during pregnancy when the potential benefit to the mother clearly outweighs the potential risk to the fetus. This decision is typically made in emergency or life-threatening situations such as peripartum cardiomyopathy or cardiogenic shock during pregnancy.

It is not known whether dobutamine is excreted in human breast milk. Given that dobutamine is used exclusively in acute, hospital-based settings and has a very short half-life (approximately 2 minutes), breastfeeding is generally not applicable during active treatment. If a patient has received dobutamine and wishes to resume breastfeeding, consultation with a healthcare professional is recommended.

How Does Dobutamine Panpharma Interact with Other Drugs?

Quick Answer: Dobutamine has clinically significant interactions with beta-blockers (which antagonize its effects), volatile anesthetics (increased arrhythmia risk), and other catecholamines (additive cardiovascular effects). MAO inhibitors can potentiate dobutamine’s effects dangerously.

Drug interactions with dobutamine are of particular clinical importance because the patients who receive this medication are typically critically ill and on multiple concurrent therapies. Understanding these interactions helps clinicians optimize therapy and minimize adverse events.

Major Interactions

Minor Interactions

The following interactions are generally manageable with dose adjustments and monitoring:

• Other catecholamines (dopamine, norepinephrine, epinephrine): Additive cardiovascular effects. Combination therapy is common in critical care but requires careful titration and continuous monitoring.
• Nitroprusside: Synergistic vasodilatory effects may enhance cardiac output improvement but can cause significant hypotension. Often used intentionally in combination.
• Calcium channel blockers: May partially attenuate the positive inotropic effects of dobutamine through reduction of intracellular calcium availability.
• Insulin and oral hypoglycaemics: Dobutamine may increase blood glucose levels, potentially requiring insulin dose adjustment in diabetic patients.
• Heparin: Dobutamine should not be mixed with heparin in the same infusion line as precipitation may occur. Use separate IV access.

What Is the Correct Dosage of Dobutamine Panpharma?

Quick Answer: The standard adult dose is 2.5–10 micrograms/kg/min by continuous intravenous infusion, titrated to clinical response. Doses up to 40 micrograms/kg/min may be used in exceptional circumstances. The solution must be diluted before administration and given via an infusion pump.

Dobutamine dosing is individualized and must be titrated to the desired hemodynamic and clinical response. The infusion rate is adjusted based on heart rate, blood pressure, cardiac output, urine output, and clinical status. Dosing requires careful calculation based on patient body weight and desired infusion rate.

Adults

Children

Dobutamine may be used in paediatric patients, including neonates, for short-term inotropic support. The typical dose range in children is 2–20 micrograms/kg/min, titrated to clinical response. Neonates may require lower starting doses due to immature hepatic enzyme systems, which can result in slower metabolism and prolonged drug effects. Continuous ECG and blood pressure monitoring is mandatory throughout administration.

The European Medicines Agency (EMA) and most international guidelines recommend that paediatric dosing be guided by clinical response, with careful attention to heart rate and blood pressure. Weight-based calculations must be meticulously verified, as small errors in paediatric dosing can have significant clinical consequences.

Elderly

Elderly patients (≥65 years) may have increased sensitivity to dobutamine due to age-related changes in cardiovascular physiology, including reduced beta-receptor density and impaired baroreceptor reflexes. It is recommended to start at the lower end of the dosing range (2.5 micrograms/kg/min) and titrate slowly. The risk of arrhythmias is higher in elderly patients, particularly those with underlying coronary artery disease.

Preparation and Administration

Dobutamine Panpharma 12.5 mg/ml must be diluted before intravenous administration. The concentrated solution should be diluted in one of the following compatible diluents:

• 0.9% sodium chloride (normal saline)
• 5% dextrose (glucose) in water
• Ringer’s lactate solution
• Sodium lactate solution

The final concentration typically ranges from 0.5 to 5 mg/ml depending on the patient’s fluid status and desired infusion rate. Administration must be via a calibrated infusion pump or syringe driver to ensure accurate dosing. Central venous access is preferred but peripheral intravenous administration is acceptable for short-term use.

Missed Dose

Since dobutamine is administered as a continuous infusion by healthcare professionals, missed doses are not applicable in the traditional sense. If the infusion is accidentally interrupted, it should be restarted as soon as possible. Due to dobutamine’s very short half-life (approximately 2 minutes), hemodynamic effects will diminish rapidly after discontinuation.

Overdose

Overdose with dobutamine manifests as excessive tachycardia, hypertension, ventricular arrhythmias (including ventricular tachycardia and ventricular fibrillation), myocardial ischaemia, nausea, vomiting, tremor, and anxiety. Due to the drug’s short half-life, signs and symptoms typically resolve rapidly upon reducing the infusion rate or discontinuing the drug. In severe cases, a short-acting beta-blocker such as esmolol may be administered cautiously to control heart rate and arrhythmias, with full resuscitation equipment available.

What Are the Side Effects of Dobutamine Panpharma?

Quick Answer: The most common side effects are dose-related cardiovascular effects including tachycardia, hypertension, and ventricular ectopic beats. Most side effects resolve when the infusion rate is reduced or stopped. Serious but rare effects include myocardial ischaemia, ventricular fibrillation, and anaphylaxis (due to sulfite content).

Like all catecholamine-based inotropic agents, dobutamine’s side effects are predominantly cardiovascular and are closely related to the dose administered. Most adverse effects are predictable extensions of the drug’s pharmacological action and are manageable by dose reduction. The critical care team continuously monitors for these effects during administration.

Tachyphylaxis (Tolerance)

A clinically important phenomenon associated with dobutamine is tachyphylaxis, or the development of tolerance with prolonged use. After approximately 72 hours of continuous infusion, the hemodynamic effects of dobutamine may diminish significantly, requiring dose escalation to maintain the same level of cardiac support. This occurs due to downregulation of beta-1 adrenergic receptors on the myocardium.

For this reason, current European Society of Cardiology (ESC) heart failure guidelines recommend limiting dobutamine use to the shortest duration necessary to stabilize hemodynamics. If longer-term inotropic support is needed, intermittent infusion protocols or alternative agents such as levosimendan (a calcium sensitizer) or milrinone (a phosphodiesterase-3 inhibitor) may be considered.

When to Report Side Effects

Because dobutamine is administered under continuous medical supervision, side effects are typically detected and managed in real time by the healthcare team. Patients and their families should report any subjective symptoms, including chest pain, palpitations, difficulty breathing, dizziness, or unusual sensations, to the nursing staff immediately. Healthcare professionals should report any suspected adverse reactions to their national pharmacovigilance centre.

How Should You Store Dobutamine Panpharma?

Quick Answer: Store unopened vials at room temperature (below 25°C), protected from light. Once diluted, the solution should be used within 24 hours. Do not freeze. Discard any unused solution.

Proper storage of dobutamine is essential to maintain drug stability and efficacy. The following storage guidelines apply to Dobutamine Panpharma 12.5 mg/ml:

• Unopened vials: Store below 25°C (77°F). Protect from light by keeping vials in the original outer carton. Do not freeze.
• Diluted solution: Once prepared, the diluted infusion solution should be used within 24 hours when stored at room temperature (20–25°C) or within 48 hours if refrigerated at 2–8°C. Any unused solution after this period should be discarded.
• Visual inspection: Before administration, inspect the solution visually. The solution should be clear and may range from colourless to slightly yellow. Solutions that are dark brown, pink, or contain visible particles must not be used. A slight pink discolouration indicates early oxidation and does not necessarily affect potency if the solution is used promptly, but significant colour change warrants disposal.
• Disposal: Any unused medicinal product or waste material should be disposed of in accordance with local pharmaceutical waste requirements. Do not pour dobutamine down the drain.

What Does Dobutamine Panpharma Contain?

Quick Answer: Each millilitre contains 12.5 mg of dobutamine (as dobutamine hydrochloride) as the active ingredient. Excipients include sodium metabisulfite (antioxidant) and water for injection.

Active Ingredient

The active ingredient is dobutamine hydrochloride, equivalent to 12.5 mg of dobutamine base per millilitre. Dobutamine hydrochloride is a synthetic catecholamine with the chemical name (±)-4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]ethyl]-1,2-benzenediol hydrochloride. Its molecular formula is C₁₈H₂₃NO₃·HCl, with a molecular weight of 337.84 g/mol.

Excipients (Inactive Ingredients)

• Sodium metabisulfite: Used as an antioxidant to prevent oxidative degradation of the dobutamine molecule. Patients with known sulfite sensitivity should be monitored closely.
• Hydrochloric acid: Used for pH adjustment (pH of solution is approximately 2.5–5.5).
• Water for injections: Solvent vehicle to appropriate volume.

The solution does not contain preservatives or antimicrobial agents, which is why strict aseptic technique must be observed during preparation and administration. Any remaining solution after use must be discarded and not stored for subsequent administration.

References

This article is based on the following peer-reviewed sources and international medical guidelines:

1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368
2. Overgaard CB, Dzavik V. Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease. Circulation. 2008;118(10):1047-1056. doi:10.1161/CIRCULATIONAHA.107.728840
3. World Health Organization. WHO Model List of Essential Medicines – 23rd list, 2023. Geneva: WHO; 2023.
4. European Medicines Agency. Dobutamine Summary of Product Characteristics (SmPC). EMA; 2024.
5. Hollenberg SM. Vasoactive Drugs in Circulatory Shock. American Journal of Respiratory and Critical Care Medicine. 2011;183(7):847-855. doi:10.1164/rccm.201006-0972CI
6. Thackray S, Easthaugh J, Freemantle N, Cleland JGF. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure – a meta-regression analysis. European Journal of Heart Failure. 2002;4(4):515-529.
7. Pellikka PA, Arruda-Olson A, Chaudhry FA, et al. Guidelines for Performance, Interpretation, and Application of Stress Echocardiography in Ischemic Heart Disease. Journal of the American Society of Echocardiography. 2020;33(1):1-41. doi:10.1016/j.echo.2019.07.001
8. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Intensive Care Medicine. 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y
9. British National Formulary (BNF). Dobutamine. NICE Evidence Services; 2025.
10. Ruffolo RR Jr. The pharmacology of dobutamine. American Journal of the Medical Sciences. 1987;294(4):244-248.

Editorial Team

This article has been written and reviewed by the iMedic Medical Editorial Team, a multidisciplinary group of healthcare professionals specialising in cardiology, critical care medicine, and clinical pharmacology.